Work

Patient and care partner perspectives on safety considerations for approved gene therapy treatments for rare diseases (from Catapult's regulatory round-up for November 2024)

Year: 2025

Type: other

Abstract: The FDA Center for Biologics Evaluation and Research (CBER) hosted a public patient listening meeting on the 20th September 2024 and opened a docket to better understand patient and care partner perspectives on safety considerations and long term follow-up for approved gene therapy treatments for rare diseases. The video recording of this meeting is available here. Published on the 3rd of december 2024. Read the entire Regulatory Round-up – November 2024 here.

Source: Industrias Culturais (Universidade de Coimbra)

DOI: 10.58079/13axm

Author: Adelage

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6954949889

Cites:

Cited by:

Related to: